GoodRx (GDRX) executive awarded 443,852 restricted stock units in new grant

Rhea-AI Filing Summary

McGinnis Christopher A reported acquisition or exercise transactions in this Form 4 filing.

GoodRx Holdings, Inc. reported that executive Christopher A. McGinnis received a grant of 443,852 restricted stock units on Class A common stock. Each unit represents a right to receive one share at no purchase price.

The restricted stock units vest in 12 equal quarterly installments, with the first vesting on April 15, 2026, and are subject to continued service through each vesting date. Following this award, McGinnis directly holds 126,321 shares of Class A common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGinnis Christopher A

(Last) (First) (Middle)

C/O GOODRX HOLDINGS, INC.

2701 OLYMPIC BOULEVARD

(Street)

SANTA MONICA CA 90404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GoodRx Holdings, Inc. [ GDRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								126,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/03/2026		A		443,852		(2)	(2)	Class A Common Stock	443,852	$0	443,852	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

2. The restricted stock units will vest ratably in 12 equal quarterly installments, with the first vesting occurring on April 15, 2026, and subject to continued service through each applicable vesting date.

Remarks:

Chief Financial Officer & Treasurer

	/s/ Gracye Cheng, Attorney-in-Fact for Christopher A McGinnis	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GoodRx (GDRX) report for Christopher A. McGinnis?

GoodRx reported that Christopher A. McGinnis received a grant of 443,852 restricted stock units. Each unit represents a right to receive one share of Class A common stock, providing equity-based compensation tied to his ongoing service with the company.

How do the new restricted stock units for GoodRx (GDRX) vest?

The 443,852 restricted stock units vest in 12 equal quarterly installments. The first vesting date is April 15, 2026, and each installment requires McGinnis to remain in continued service through the applicable vesting date before shares are delivered.

What does each GoodRx (GDRX) restricted stock unit represent in this Form 4?

Each restricted stock unit represents a contingent right to receive one share of GoodRx Class A common stock. No purchase price is required, but delivery of shares depends on the vesting schedule and McGinnis meeting the continued service conditions described in the filing.

What is Christopher A. McGinnis’s GoodRx (GDRX) stock position after this Form 4?

After the reported transactions, Christopher A. McGinnis directly holds 126,321 shares of GoodRx Class A common stock. He also has 443,852 restricted stock units outstanding, which may convert into additional shares over time as the quarterly vesting requirements are satisfied.

Is the GoodRx (GDRX) Form 4 transaction a stock purchase or a grant?

The Form 4 shows a grant or award acquisition of restricted stock units, not an open-market stock purchase. The transaction is coded as an award, with vesting over time rather than an immediate cash purchase of GoodRx Class A common shares in the market.